IP Library › Patent Application 14849950
Patent Application
App. No. 14/849,950

Pulmonary Delivery for Levodopa

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/849,950
Abstract

In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.

Claims (16)

1 . A composition of dry powder particles formulated for pulmonary delivery comprising about 75 weight percent levodopa or more and sodium chloride.

2 . The composition of claim 1 , wherein the particles further comprise a phospholipid or a combination of phospholipids.

3 . The composition of claim 1 , wherein the particles have a tap density about 0.4 g/cm 3 or less.

4 . The composition of claim 1 , wherein the particles have a volume median geometric diameter about 5 micrometers or more.

5 . The composition of claim 1 , wherein the particles have an aerodynamic diameter of from about 1 micrometer to about 5 micrometers.

6 . The composition of claim 1 , wherein the particles have an aerodynamic diameter of from about 1 micrometer to about 3 micrometers.

7 . The composition of claim 1 , wherein the particles have an aerodynamic diameter of from about 3 micrometer to about 5 micrometers.

8 . The composition of claim 1 , wherein the particles have a tap density about 0.3 g/cm 3 or less.

9 . The composition of claim 1 , wherein the particles have a tap density about 0.2 g/cm 3 or less.

10 . The composition of claim 1 , wherein the particles have a tap density about 0.1 g/cm 3 or less.

11 . The composition of claim 1 , wherein the particles comprise about 10% or less by weight of sodium chloride.

12 . The composition of claim 1 , wherein the particles comprise about 5% or less by weight of sodium chloride.

13 . The composition of claim 1 , wherein the particles comprise about 2% or less by weight of sodium chloride.

14 . The composition of claim 2 , wherein the phospholipid is dipalmitoyl phosphatidylcholine (DPPC).

15 . A composition of dry powder particles consisting essentially of about 75% or more levodopa, sodium chloride and dipalmitoylphosphatidylcholine.

16 . A composition of dry powder particles consisting essentially of levodopa, sodium chloride and dipalmitoylphosphatidylcholine, wherein the ratio of levodopa:dipalmitoylphosphatidylcholine:sodium chloride is about 90:8:2.